Abstract:
This invention generally relates to derivatives of 3,6 disubstituted azabicyclo hexanes. The compounds of this invention can function as muscarinic receptor antagonists and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to pharmaceutical compositions containing the compounds of the present invention and the methods of treating the diseases mediated through muscarinic receptors.
Abstract:
Novel synthesis methods, to the products of such novel methods, and to uses of these products. In particular, the present invention provides methods for the reactions of furanones, in particular fimbrolides, with amines. The invention has particular application in the synthesis of halogenated 1,5-dihydro-pyrrol-2-one, 5-halomethylene substituted 1,5-dihydropyrrol-2-ones (lactam analogues of fimbriolides), 5-amino substituted furanones and 5-aminomethylene-2(5H)-furanones and their synthetic analogues. The invention also relates to novel compounds and uses thereof.
Abstract:
The invention relates to a cost effective and industrially advantageous process for the selective methylation of a hydroxy group at the 6 position of erythromycin A derivative which comprised methylating the erythromycin A derivative with a methylating agent in a mixture of toluene and a ploar aprotic solvent.
Abstract:
A multistep process for producing 8-chloro-6-(2-fluorophenyl)-1-methyl-4-H-imidazo�1,5a!�1,4! benzodiazepine (midazolam) comprises treating a compound of Formula II with a lower alkyl dithiol to produce a compound of Formula III, wherein n=2 or 3, converting the compound of Formula III to a compound of Formula VII, and then treating the compound of Formula VII with a deprotecting agent, thereby producing midazolam. Novel intermediate compounds are also disclosed.
Abstract:
An agglomeration process in which clay fines alone or in combination with other materials are agglomerated to a usable pellet size for a variety of marketable end products. The clay fines are collected, prepared and blended with conditioners and/or other waste materials in the proportions necessary to produce the desired pellet characteristics. The blended materials are preweighed and measured, permitting batch feeding to the agglomerator. The agglomerated pellets are dried and screened, with the oversize pellets being passed through a granulator to reduce their size and then being rescreened, and the undersized pellets being recycled to the collecting step for reagglomeration. Hence, the process provides pellets of relatively uniform size with little or no waste from the agglomeration procedure. The pellets may be impregnated or coated with a variety of substances, including fertilizers, pesticides, odor reducing substances, and colorants to provide a variety of different end products, including cat box filler, fertilizers, soil conditioners and floor absorbent.
Abstract:
The invention provides small molecule modulators of retinoic acid receptor-related orphan receptors such as RORα, RORβ, or RORγ, of formula with the variable atoms as defined herein and R1 comprising a hydroxyl- or alkoxyl-substituted fluoroalkyl group. Compounds of the invention can be effective modulators at concentrations ineffective to act on LXR receptors, or on other nuclear receptors, or other biological targets. Methods of modulation the RORs and methods of treating metabolic disorders, immune disorders, cancer, and CNS disorders wherein modulation of an ROR is medically indicated are also provided.
Abstract:
One embodiment of the present invention provides a system that facilitates accessing a credential. During operation, the system receives a request at a credentials-storage framework (CSF) to retrieve the credential. If a target credential store containing the credential is not already connected to the CSF, the system looks up a bootstrap credential for the target credential store in a bootstrap credential store, which contains bootstrap credentials for other credential stores. Next, the system uses this bootstrap credential to connect the CSF to the target credential store. Finally, the system retrieves the credential from the target credential store, and returns the credential to the requestor.
Abstract:
The present invention relates to 6-substituted isoflavonoid compounds and compositions comprising same. The invention further relates to the use of 6-substituted isoflavonoid compounds for the treatment of various diseases and conditions.
Abstract:
The present invention provides Gyrase B and/or Topoisomerase IV par E inhibitors, which can be used as antibacterial agents. Compounds disclosed herein can be used for treating or preventing conditions caused by or contributed by gram positive, gram negative and anaerobic bacteria, more particularly against, for example, Staphylococci, Streptococci, Enterococci, Haemophilus, Pseudomonas spp., Acenetobacter spp., Moraxalla spp., Chlamydia spp., Mycoplasma spp., Legionella spp., Ktycobacterium spp., Helicobacter, Clostridium spp., Bacteroides spp., Corynebacterium, Bacillus spp., Enterobactericeae,’ (E. coli, Klebsiella spp., Proteus spp., etc.) or any combination thereof. Also provided, are processes for preparing compounds disclosed herein, pharmaceutical compositions containing compounds disclosed herein, and methods of treating bacterial infections. (Formula)